India's autoinjector and pen-injector market changed overnight on March 20, 2026. That day, the Indian patent on semaglutide expired, and around ten Indian drug makers rushed generic versions to market in pens, vials and reusable devices. At the same time, Indian biosimilar makers are winning US approvals for autoinjector presentations, and a home-grown device industry is scaling up to supply the pens. This analysis maps ten companies shaping the market, from Biocon Biologics and Zydus to device maker Shaily Engineering Plastics.

Why autoinjectors matter in India right now

Three forces are driving demand. First, the end of semaglutide exclusivity has turned GLP-1 injections from a premium import into a mass-market category. Nomura estimates India's semaglutide market could grow from about $168 million today to about $1.26 billion within five years, and most of that volume will be delivered by pen. Second, Indian biosimilar makers now compete abroad on device convenience, not just price, which pushes them to develop autoinjector presentations. Third, India is building its own device supply chain, so pens no longer have to be imported to reach patients at Indian prices.

India autoinjector value chain

The Indian market links drug makers with device makers and specialist contract manufacturers.

Momentum is building: milestone timeline

Counting the dated pen and autoinjector milestones from the companies below shows how fast the market is moving. One milestone came in 2024 and three in 2025; five more arrived in the first eight months of 2026.

The semaglutide price war

Generic launches have cut the monthly cost of semaglutide sharply. Pens sit at the top of the generic price range and vials at the bottom, which shows how much patients value the convenience of a pen.

Company analysis

Biocon Biologics Limited

Biocon Biologics is India's leading biosimilar exporter with an autoinjector story. Its ustekinumab biosimilar Yesintek was first approved by the US FDA in November 2024 and launched in the US in February 2025 (US launch release). On August 18, 2026 the FDA approved a single-dose prefilled autoinjector in 45 mg/0.5 mL and 90 mg/mL strengths, and Biocon has also received Health Canada approval for a Yesintek autoinjector pen. The autoinjector matters because eight ustekinumab biosimilars now compete in the US. More: about Biocon Biologics, Biocon Biologics home, contact, 2026 annual report, 2025 annual report.

Sun Pharmaceutical Industries Ltd.

Sun Pharma is India's largest drug maker and has both a legacy injector product and a new GLP-1 pen. It markets a sumatriptan injection for migraine and lists injectables in its European product range. In March 2026 it launched generic semaglutide in India in pen form under two brands, Sematrinity for diabetes and Noveltreat for weight management, at up to about $84 a month for obesity doses. Its subsidiary Taro has also launched a methylphenidate ER product in Canada. More: about Sun Pharma, Sun Pharma home, contact, 2024-25 annual report.

Dr. Reddy’s Laboratories Limited

Dr. Reddy's combines a US autoinjector-format generic with a domestic GLP-1 pen. In the US it sells sumatriptan injection. In India it launched generic semaglutide as the Obeda pen at about $44 a month, and it is adapting to India's new semaglutide manufacturing and testing standards. It also announced a first-to-market US launch of sugammadex injection in July 2026. More: about Dr. Reddy’s, Dr. Reddy’s home, contact, 2025-26 annual report, 2024-25 annual report.

Shaily Engineering Plastics Ltd.

Shaily is the device maker behind India's pen boom. It designs and manufactures platform pen injectors, including TOBY and AXIOM MAX (see its full platform device range). Its spring-driven ShailyPen Neo has been commercially available in India since March 2026 as part of a customer's semaglutide product, has a US FDA tentative approval for a generic semaglutide combination product, and has launched in Canada through a partner (approval coverage). In February 2026 Shaily won an order worth about $45 million to supply pen injectors to a domestic drug maker over four years, and it plans capacity of 80 million pens by July 2026, all of it already contracted. More: about Shaily, Shaily home, contact, 2026 annual report, 2025 annual report.

Dharma Biologics

Dharma Biologics is a Bengaluru-based contract developer and manufacturer focused on autoinjector development. It offers integrated drug-device development, autoinjector-ready formulation work, aseptic fill-finish of syringes and cartridges with device assembly, human-factors engineering and regulatory support for combination products. That makes it a partner for drug makers that want an autoinjector without building the capability in-house. More: Dharma Biologics home, contact.

Zydus Lifesciences Limited

Zydus has made semaglutide its flagship injectable play. It planned an innovative semaglutide injection for day one of patent expiry, launched at about $23 a month, and widened its reach through a licensing deal with Torrent Pharma to co-market it and a similar agreement with Lupin (launch coverage). Zydus has also secured a US FDA nod for a scurvy injection generic; see its product range. More: about Zydus, Zydus home, contact, 2023-24 annual report, Q4 results.

Lupin Limited

Lupin is building a complex-injectables business in the US. On October 3, 2025 it launched liraglutide injection in a single-patient-use prefilled pen in the US, a generic of Victoza, whose reference product had about $350 million in annual US sales (US release). It also launched Rymti, a biosimilar etanercept, in Canada. Its PrecisionSphere long-acting injectable platform produced a risperidone long-acting injectable, and in October 2025 Lupin opened the platform to partners. It also launched glucagon for injection in the US. More: about Lupin, Lupin home, contact, 2026 financial statements, 2025 integrated report.

Aurobindo Pharma Limited

Aurobindo brings manufacturing scale through its injectables arm Eugia and its API business Apitoria. Recent activity includes a US FDA approval for plerixafor injection and an inspection of its AuroPeptides facility that ended with one FDA observation, a peptide capability that matters for GLP-1 supply. More: about Aurobindo, Aurobindo home, contact, 2023-24 annual report, 2025 integrated report.

Wockhardt Limited

Wockhardt is an established Indian injectables and biotech company. It does not list an autoinjector product today, which makes it a player to watch rather than a current competitor. More: chairman’s profile, Wockhardt home, contact, 2025-26 annual report, 2024-25 annual report.

Intas Pharmaceuticals Limited

Intas is one of India's largest privately held drug makers, with a strong biosimilars business in Europe through its subsidiary Accord. It does not publish an autoinjector product page, but its biosimilar reach makes it a likely future entrant. More: about Intas, Intas home, contact, company profile.

Therapy-area coverage matrix

Where each company plays, based on the products and announcements linked above. A full dot means a marketed product or platform; a half dot means a pipeline, adjacent or indirect role.

SWOT analysis of the India autoinjectors market

Competitive landscape

The map below places each company by how strong its drug brands are versus how much it owns device and manufacturing capability.

Vendor landscape

Indian vendors fall into three tiers, from integrated brand owners at the top to device and contract-manufacturing enablers at the base.

Competitive environment: five forces

Rivalry and buyer power are both high, because many firms launched the same molecule at once into a price-sensitive, mostly out-of-pocket market.

Merger, partnership and deal analysis

Indian deal flow is led by co-marketing, licensing and supply contracts rather than acquisitions.

Strategy framework

Winning in Indian pens and autoinjectors follows a five-step path. Each step shows which companies are strongest there.

Heat map analysis

Each company is scored from 1 (low) to 5 (high) on six factors, based on the products, filings and deals cited in this article. Darker cells show greater strength.

Scores are an indicative editorial assessment, not market share. Full company benchmarking is in the report.

Five trends to watch

1. The pen becomes a mass-market product. Generic semaglutide has put pen injectors in reach of millions of Indian patients.
2. Price tiers by device. Disposable pens, reusable pens and vials now sell at very different prices for the same drug.
3. Made-in-India devices. Shaily's ShailyPen Neo shows Indian firms can design, make and export pen injectors.
4. Biosimilars add autoinjectors. Biocon's Yesintek autoinjector shows device upgrades are now part of competing abroad.
5. Contract manufacturing grows. CDMOs like Dharma Biologics and Aurobindo's Eugia can make autoinjectors for others.

Frequently asked questions